Last reviewed · How we verify

Intra-arterial infusion of Alteplase

Central Hospital, Nancy, France · Phase 3 active Small molecule

Intra-arterial infusion of Alteplase is a Fibrinolytic agent / Tissue plasminogen activator (tPA) Small molecule drug developed by Central Hospital, Nancy, France. It is currently in Phase 3 development for Acute ischemic stroke (intra-arterial thrombolysis), Acute arterial thrombosis, Peripheral arterial occlusion.

Alteplase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, directly dissolving fibrin clots when delivered intra-arterially.

Alteplase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, directly dissolving fibrin clots when delivered intra-arterially. Used for Acute ischemic stroke (intra-arterial thrombolysis), Acute arterial thrombosis, Peripheral arterial occlusion.

At a glance

Generic nameIntra-arterial infusion of Alteplase
SponsorCentral Hospital, Nancy, France
Drug classFibrinolytic agent / Tissue plasminogen activator (tPA)
TargetPlasminogen / Fibrin
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Alteplase binds to fibrin in thrombi and catalyzes the conversion of plasminogen to plasmin, which degrades the fibrin matrix of blood clots. When administered via intra-arterial infusion, it achieves high local concentrations at the site of thrombosis, enabling rapid clot lysis with potentially reduced systemic fibrinolytic effects compared to intravenous administration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intra-arterial infusion of Alteplase

What is Intra-arterial infusion of Alteplase?

Intra-arterial infusion of Alteplase is a Fibrinolytic agent / Tissue plasminogen activator (tPA) drug developed by Central Hospital, Nancy, France, indicated for Acute ischemic stroke (intra-arterial thrombolysis), Acute arterial thrombosis, Peripheral arterial occlusion.

How does Intra-arterial infusion of Alteplase work?

Alteplase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, directly dissolving fibrin clots when delivered intra-arterially.

What is Intra-arterial infusion of Alteplase used for?

Intra-arterial infusion of Alteplase is indicated for Acute ischemic stroke (intra-arterial thrombolysis), Acute arterial thrombosis, Peripheral arterial occlusion.

Who makes Intra-arterial infusion of Alteplase?

Intra-arterial infusion of Alteplase is developed by Central Hospital, Nancy, France (see full Central Hospital, Nancy, France pipeline at /company/central-hospital-nancy-france).

What drug class is Intra-arterial infusion of Alteplase in?

Intra-arterial infusion of Alteplase belongs to the Fibrinolytic agent / Tissue plasminogen activator (tPA) class. See all Fibrinolytic agent / Tissue plasminogen activator (tPA) drugs at /class/fibrinolytic-agent-tissue-plasminogen-activator-tpa.

What development phase is Intra-arterial infusion of Alteplase in?

Intra-arterial infusion of Alteplase is in Phase 3.

What are the side effects of Intra-arterial infusion of Alteplase?

Common side effects of Intra-arterial infusion of Alteplase include Intracranial hemorrhage, Systemic bleeding, Reperfusion injury, Allergic reaction.

What does Intra-arterial infusion of Alteplase target?

Intra-arterial infusion of Alteplase targets Plasminogen / Fibrin and is a Fibrinolytic agent / Tissue plasminogen activator (tPA).

Related